ArticleFrontiers in pharmacology2026
AI-driven network pharmacology and multi-omics validation identify KCNH2 as a prognostic biomarker and candidate therapeutic vulnerability of Acorus tatarinowii in glioblastoma.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioblastoma (GBM) remains a highly aggressive malignancy with limited effective therapeutic options. Integrating traditional medicine resources with artificial intelligence-based analytical strategies may accelerate the identification of novel biomarkers and drug targets. Methods: We applied a network pharmacology framework to screen bioactive compounds of Acorus tatarinowii and identify intersecting targets with GBM-related genes. LASSO Cox regression was performed in TCGA-GBM to construct a prognostic model. Multi-omics analyses, including transcriptomic validation, CPTAC proteomics, copy-number alteration profiling, mutation landscape characterization, immune infiltration assessment, and pharmacogenomic correlation analysis, were conducted to prioritize key targets. Functional experiments based on genetic perturbation of KCNH2, including colony formation, CCK-8 proliferation, wound-healing, apoptosis assays, mitochondrial membrane potential measurement, and xenograft models, were performed to evaluate its biological effects. Results: Twenty-five intersecting targets were identified, and an eight-gene LASSO signature demonstrated favorable prognostic performance. Among these genes, KCNH2 showed consistent transcriptomic upregulation, proteomic validation, association with genomic instability, immune modulation patterns, and drug sensitivity correlations. Functional assays confirmed that KCNH2 silencing suppressed proliferation and migration-associated behavior while inducing mitochondria-dependent apoptosis in GBM cells. Conclusion: This integrative AI-driven and multi-omics strategy identifies KCNH2 as a biologically relevant and translationally informative candidate target potentially linked to the anti-glioma effects of Acorus tatarinowii. These findings highlight the value of combining traditional medicine resources with computational prioritization and experimental validation to uncover biologically actionable mechanisms in GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.